Bioavailability of testosterone enanthate dependent on genetic variation in the phosphodiesterase 7B but not on the uridine 5′-diphospho- glucuronosyltransferase (UGT2B17) gene.

Pharmacogenetics and Genomics

Volumn 21, Issue 6, 2011, Pages 325-332

  Ekström, Lena ^a   Schulze, Jenny J ^a   Guillemette, Chantal ^b   Belanger, Alain ^b   Rane, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

phosphodiesterase; testosterone; testosterone glucuronide and epitestosterone glucuronide ratio; uridine 50 diphospho glucuronosyltransferase

Indexed keywords

BIOLOGICAL MARKER; EPITESTOSTERONE; GLUCURONOSYLTRANSFERASE; PHOSPHODIESTERASE 7B; PHOSPHODIESTERASE VII; TESTOSTERONE; TESTOSTERONE ENANTATE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; DOPING; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG HYDROLYSIS; GENE; GENE DELETION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER HOMOGENATE; MAJOR CLINICAL STUDY; MALE; PDE7B GENE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TESTOSTERONE BLOOD LEVEL; UGT2B17 GENE;

EID: 79955918355     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328344c5c6     Document Type: Article

References (30)

1. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol 2006; 65:275-281.
2. Sjoqvist F, Garle M, Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. Lancet 2008; 371:1872-1882. (Pubitemid 351734542)
3. Donike M, Brwald KR, Klostermann K, Schänzer W, Zimmerman J. Detection of exogenous testosterone. Nachweis von exogenem testosteron Sport: Leistung und Gesundheit, Kongressbd. Dtsch Sportarztekongress. Köln:̈ Deutcher Artzte-Verlag; 1983. pp. 293-298.
4. Donike M, Ueki M, Kuroda Y, Geyer H, Nolteernsting E, Rauth S, et al. Detection of dihydrotestosterone (DHT) doping: alterations in the steroid profile and reference ranges for DHT and its 5 alpha-metabolites. J Sports Med Phys Fitness 1995; 35:235-250. (Pubitemid 26122658)
5. Jakobsson J, Ekstrom L, Inotsume N, Garle M, Lorentzon M, Ohlsson C, et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab 2006; 91:687-693. (Pubitemid 43236944)
6. Sten T, Bichlmaier I, Kuuranne T, Leinonen A, Yli-Kauhaluoma J, Finel M. UDP-glucuronosyltransferases (UGTs) 2B7 and UGT2B17 display converse specificity in testosterone and epitestosterone glucuronidation, whereas UGT2A1 conjugates both androgens similarly. Drug Metab Dispos 2009; 37:417-423.
7. Wilson W III, Pardo-Manuel de Villena F, Lyn-Cook BD, Chatterjee PK, Bell TA, Detwiler DA, et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 2004; 84:707-714. (Pubitemid 39310948)
8. Schulze JJ, Lundmark J, Garle M, Skilving I, Ekstrom L, Rane A. Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J Clin Endocrinol Metab 2008; 93:2500-2506. (Pubitemid 352008513)
9. Schulze JJ, Lundmark J, Garle M, Ekstrom L, Sottas PE, Rane A. Substantial advantage of a combined Bayesian and genotyping approach in testosterone doping tests. Steroids 2009; 74:365-368.
10. Labrie F, Belanger A, Belanger P, Berube R, Martel C, Cusan L, et al. Metabolism of DHEA in postmenopausal women following percutaneous administration. J Steroid Biochem Mol Biol 2007; 103:178-188. (Pubitemid 46157181)
11. Hsing AW, Stanczyk FZ, Belanger A, Schroeder P, Chang L, Falk RT, et al. Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry. Cancer Epidemiol Biomarkers Prev 2007; 16:1004-1008. (Pubitemid 46910104)
12. Chung BC, Choo HY, Kim TW, Eom KD, Kwon OS, Suh J, et al. Analysis of anabolic steroids using GC/MS with selected ion monitoring. J Anal Toxicol 1990; 14:91-95.
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-275.
14. Narayanan R, LeDuc B, Williams DA. Determination of the kinetics of rat UDP-glucuronosyltransferases (UGTs) in liver and intestine using HPLC. J Pharm Biomed Anal 2000; 22:527-540. (Pubitemid 30151242)
15. Schulze JJ, Rane A, Ekstrom L. Genetic variation in androgen disposition: implications in clinical medicine including testosterone abuse. Expert Opin Drug Metab Toxicol 2009; 5:731-744.
16. Back DJ, Breckenridge AM, Chapman CR, Crawford FE, Olsen KA, Orme ML, et al. Studies on the enzymatic cleavage of norethisterone oenanthate. Contraception 1981; 23:125-132. (Pubitemid 11113147)
17. Hetman JM, Soderling SH, Glavas NA, Beavo JA. Cloning and characterization of PDE7B: a cAMP-specific phosphodiesterase. Proc Natl Acad Sci USA 2000; 97:472-476. (Pubitemid 30055855)
18. Sasaki T, Kotera J, Yuasa K, Omori K. Identification of human PDE7B: a cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 2000; 271:575-583. (Pubitemid 30444670)
19. Gardner C, Robas N, Cawkill D, Fidock M. Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun 2000; 272:186-192. (Pubitemid 30444920)
20. Zhang L, Murray F, Zahno A, Kanter JR, Chou D, Suda R, et al. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2008; 105:19532-19537.
21. Ikeda M, Tomita Y, Mouri A, Koga M, Okochi T, Yoshimura R, et al. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol Psychiatry 2010; 67:263-269.
22. Di Luigi L, Sgro P, Romanelli F, Mazzarino M, Donati F, Bragano MC, et al. Urinary and serum hormones profiles after testosterone enanthate administration in male hypogonadism: concerns on the detection of doping with testosterone in treated hypogonadal athletes. J Endocrinol Invest 2009; 32:445-453.
23. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004; 89:3813-3817. (Pubitemid 39071477)
24. Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 2007; 92:3844-3853. (Pubitemid 47607632)
25. Zitzmann M. Mechanisms of disease: pharmacogenetics of testosterone therapy in hypogonadal men. Nat Clin Pract Urol 2007; 4:161-166. (Pubitemid 46416281)
26. Hu DG, Gardner-Stephen D, Severi G, Gregory PA, Treloar J, Giles GG, et al. A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3alpha,17beta-diol glucuronide. Mol Pharmacol 2010; 78:714-722.
27. Belanger A, Pelletier G, Labrie F, Barbier O, Chouinard S. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol Metab 2003; 14:473-479. (Pubitemid 37517349)
28. Chouinard S, Pelletier G, Belanger A, Barbier O. Isoform-specific regulation of uridine diphosphate-glucuronosyltransferase 2B enzymes in the human prostate: differential consequences for androgen and bioactive lipid inactivation. Endocrinology 2006; 147:5431-5442. (Pubitemid 44790598)
29. Sten T, Kurkela M, Kuuranne T, Leinonen A, Finel M. UDP- glucuronosyltransferases in conjugation of 5alpha-and 5beta-androstane steroids. Drug Metab Dispos 2009; 37:2221-2227.
30. Kuuranne T, Kurkela M, Thevis M, Schanzer W, Finel M, Kostiainen R. Glucuronidation of anabolic androgenic steroids by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 2003; 31:1117-1124. (Pubitemid 37048283)